In Enterobacterales bacteremia, antipseudomonal β-lactam de-escalation was noninferior to continuation for clinical cure at 3 to 5 d
Annals of Internal Medicine · 2024
DOI: 10.7326/j24-0030 ↗Kurz gefasst
Kommentar in der Zeitschrift Annals of Internal Medicine, 2024. Verfasst von Konstantinos Ouranos und 1 weiteren Autor:innen. Beteiligte Einrichtung: Houston Methodist Hospital, Houston, Texas, USA (K.O., E.M.). Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Bacteremia, beta-Lactams, Enterobacteriaceae Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 2 Literaturangaben.
Abstract (Originalsprache)
SOURCE CITATION: López-Cortés LE, Delgado-Valverde M, Moreno-Mellado E, et al; SIMPLIFY study group. Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial. Lancet Infect Dis. 2024;24:375-385. 38215770.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Houston Methodist Hospital, Houston, Texas, USA (K.O., E.M.).
Zitieren
APA
Ouranos, K., & Mylonakis, E. (2024). In Enterobacterales bacteremia, antipseudomonal β-lactam de-escalation was noninferior to continuation for clinical cure at 3 to 5 d. Annals of Internal Medicine. https://doi.org/10.7326/j24-0030
Vancouver
Ouranos K, Mylonakis E. In Enterobacterales bacteremia, antipseudomonal β-lactam de-escalation was noninferior to continuation for clinical cure at 3 to 5 d. Annals of Internal Medicine. 2024. doi:10.7326/j24-0030
BibTeX
@article{Ouranos2024,
author = {Ouranos, Konstantinos and Mylonakis, Eleftherios},
title = {In Enterobacterales bacteremia, antipseudomonal β-lactam de-escalation was noninferior to continuation for clinical cure at 3 to 5 d},
journal = {Annals of Internal Medicine},
year = {2024},
doi = {10.7326/j24-0030}
}
EUVIMED